Welcome Note

The Conference will aim to deal with all aspects related to early diagnosis, 120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.

120 to 139 mm Hg and 80 to 89 mm Hg, respectively.

Prehypertension is associated with other components of the metabolic syndrome i.e. obesity, glucose intolerance and dyslipidemia. The association is due to common mechanistic pathways and has implications on cardiovascular complications. Diet and exercise but not drug therapy benefit all components of the metabolic syndrome. Antihypertensive medications may lead to deterioration in glucose tolerance while glucose lowering agents may affect blood pressure. Thus, any discussion about prehypertension must be done in context to the whole cardio metabolic risk.

Systolic blood pressure (BP) of less than 140 mm Hg and diastolic BP less than 90 mm Hg were for years considered as normal. Mounting evidence suggests that BP in the high reference range is associated with an increased risk of cardiovascular disease. The ESH report of 2006 defined it as “high normal” while the seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure defined a new BP category “Prehypertension” for systolic and diastolic BP.

The Conference will aim to deal with all aspects related to early diagnosis.
Committees

Co-Chairs
Daniel A. Duprez, USA
Hermann Haller, Germany
Basil S. Lewis, Israel
Reuven Zimlichman, Israel

Organizing Committee
Luis M. Ruilope, Spain, Chair
Olga Gonzalez Albarran
Sara Artola
Mariano de la Figuera
Josep Maria Galcerán
Ramon Gomis
Jose Zamorano

Scientific Committee
Giuseppe Ambrosio, Italy
Raffaele Bugiardini, Italy
John R. Cockcroft, UK
Peter W. de Leeuw, Netherlands
Cetin Erol, Turkey
Raimund Erbel, Germany
Csaba Farsang, Hungary
Pavel Hamet, Canada
Anthony M. Heagerty, UK
Uday Jadhav, India
Andrzej Januszewicz, Poland
Petr Kala, Czech Republic
Sverre E. Kjeldsen, Norway
Carmel McEniery, UK
Itamar Raz, Israel
Alexander R. Rosenkranz, Austria
Talma Rosenthal, Israel
Hiroyuki Sasamura, Japan
Guntram Schernthaner, Austria
Oliver Steinbach, Netherlands
Thomas Unger, Germany
Romeo J. Vecht, Israel
Joe Vita, USA
Charalambos Vlachopoulos, Greece
Bruno Watschinger, Austria
Thomas Weber, Austria
Ian B. Wilkinson, UK
Yuqing Zhang, China

Honorary Chairmen
Stevo Julius, USA  Giuseppe Mancia, Italy

Conference topics will include
- Metabolic Syndrome and Vitamin D
- Prediabetes - Mechanisms, Diagnosis and Management
- Pre Levels of CV Risk Factors - Boosting Risk of Events and Deciding Who Should be Treated
- Benefits of Achieving Optimal Risk Factors Level - When, How and with What?
- Prehypertension and Metabolic Syndrome in Different Populations - Epidemiologic Aspects
- Total Cardiovascular Risk Evaluation and Management
- Arterial Properties, Evaluation and Treatment in Metabolic Syndrome Patients
- Cardiac Markers of Preclinical Disease in Metabolic Syndrome Patients
- Effect of Pre Disease Risk Factors in Patients with the Metabolic Syndrome on Morbidity and Mortality
- Which Elderly Patients with Pre Disease should be Considered for Medical Treatment
- Children and Adolescents: Prehypertension and Metabolic Syndrome, Progression of Risk and Diagnosis of Disease
- The Heart, the Brain and the Kidney in Pre Disease and the Metabolic Syndrome

The full topic list can be viewed at the Conference website: www.prehypertension.org

Call for Abstracts
The Scientific Committee encourages the submission of original abstracts for oral and poster presentations. All submitted abstracts will be reviewed by the Scientific Committee. If an abstract is accepted, the presenting author is required to register to attend the conference.